Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79149.421.4809%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Cellectis SA

CLLSNASDAQ
Trade with Public
Trade with Public
$3.24
-0.08-2.41%
At close: Sep 4, 5:00 PM EST
$3.25
0.010.31%
After Hours: Sep 3, 5:56 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareOptionsStock Report

Cellectis Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cellectis (CLLS).

Price Target Range — 6 Quarters

Analyst Consensus — 5 Analysts

2S.Buy
3Buy
Consensus RatingOverweight# Analysts5Avg. Consensus PT$8Upside to Avg. PT+156.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 28, 2026BarclaysLukas ShumwayInitiateOverweight$9
Apr 14, 2026CitizensSilvan TurkcanMaintainedMarket Outperform$8
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Initiates Coverage On Cellectis with Overweight Rating, Announces Price Target of $9

Barclays analyst Lukas Shumway initiates coverage on Cellectis (NASDAQ:CLLS) with a Overweight rating and announces Price Target of $9.
Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Cellectis, Maintains $8 Price Target

Citizens analyst Silvan Turkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and maintains $8 price target.
Benzinga Newsdesk

Allogene Therapeutics Stock Hits 52-Week High - Here's Why

Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to delay relapse in lymphoma patients.
Vandana Singh

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Avi Kapoor

PRO
Clear Street Initiates Coverage On Cellectis with Buy Rating, Announces Price Target of $9

Clear Street analyst Bill Maughan initiates coverage on Cellectis (NASDAQ:CLLS) with a Buy rating and announces Price Target of $9.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Cellectis, Raises Price Target to $8

Barclays analyst Gena Wang maintains Cellectis (NASDAQ:CLLS) with a Overweight and raises the price target from $4 to $8.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved